USFDA issues 3 observations for Zydus Lifesciences Ahmedabad facility
The inspection was a Pre-Approval Inspection as well as a GMP Audit.
Ahmedabad: Drug major, Zydus Lifesciences, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with three observations at the company's manufacturing facility SEZ-1 located at Pharmez, Ahmedabad.
The inspection was held from March 20 to 24, 2023.
"The inspection was a Pre-Approval Inspection (PAI) as well as a GMP Audit and concluded with three observations. There were no Data Integrity related observations," the company said in a BSE filing.
"The Company is addressing these observations and will respond to them within the stipulated time," Zydus added.
Medical Dialogues team had earlier reported that USFDA had concluded a Pre-Approval Inspection (PAI) with two observations at the SEZ, Ahmedabad facility of Zydus Animal Health and Investments Limited, a wholly owned subsidiary of Zydus Lifesciences Limited.
Zydus Lifesciences Limited, Formerly known as Cadila Healthcare Limited, is an Indian Pharmaceutical company headquartered in Ahmedabad. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. It is primarily engaged in the manufacture of generic drugs.
Read also: Zydus Lifesciences Depression drug Doxepin Hydrochloride bags USFDA okay
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd